LPTX vs. SLS, ANEB, DERM, ASRT, IFRX, TPST, MNOV, SPRO, YS, and CUE
Should you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include SELLAS Life Sciences Group (SLS), Anebulo Pharmaceuticals (ANEB), Journey Medical (DERM), Assertio (ASRT), InflaRx (IFRX), Tempest Therapeutics (TPST), MediciNova (MNOV), Spero Therapeutics (SPRO), YS Biopharma (YS), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical preparations" industry.
SELLAS Life Sciences Group (NASDAQ:SLS) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability and media sentiment.
Leap Therapeutics received 279 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 68.65% of users gave Leap Therapeutics an outperform vote while only 58.82% of users gave SELLAS Life Sciences Group an outperform vote.
SELLAS Life Sciences Group has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
SELLAS Life Sciences Group's return on equity of -133.17% beat Leap Therapeutics' return on equity.
SELLAS Life Sciences Group has higher earnings, but lower revenue than Leap Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
SELLAS Life Sciences Group presently has a consensus price target of $3.00, suggesting a potential upside of 97.37%. Leap Therapeutics has a consensus price target of $11.38, suggesting a potential upside of 258.83%. Given SELLAS Life Sciences Group's higher probable upside, analysts plainly believe Leap Therapeutics is more favorable than SELLAS Life Sciences Group.
17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 1.6% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 11.3% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, SELLAS Life Sciences Group and SELLAS Life Sciences Group both had 1 articles in the media. Leap Therapeutics' average media sentiment score of 0.00 equaled SELLAS Life Sciences Group'saverage media sentiment score.
Summary
Leap Therapeutics beats SELLAS Life Sciences Group on 10 of the 14 factors compared between the two stocks.
Get Leap Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Leap Therapeutics Competitors List
Related Companies and Tools
